Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASLAN004 in Healthy Subjects
NCT03721263Phase 1Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Mar 2019
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eblasakimab in atopic dermatitis (AD), sponsored by ASLAN Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at 85 days. Started Oct 2018; status: completed.
02
Drugs
eblasakimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03721263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721263.